These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36977394)

  • 41. Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
    Chatzistamatiou K; Tsertanidou A; Moysiadis T; Mouchtaropoulou E; Pasentsis K; Skenderi A; Stamatopoulos K; Agorastos T
    Gynecol Oncol; 2021 Sep; 162(3):560-568. PubMed ID: 34210517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of cervical high-grade squamous intraepithelial lesions and assessing diagnostic performance of colposcopy among women with oncogenic HPV.
    Li X; Xiang F; Zhao Y; Li Q; Gu Q; Zhang X; Chen Z; Zhang M; Wang J; Liu R; Kang X; Wu R
    BMC Womens Health; 2023 Aug; 23(1):411. PubMed ID: 37542333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence of cervical high-grade squamous intraepithelial lesions and squamous cell carcinoma in women with high-risk human papillomavirus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype.
    Gu L; Hong Z; Gao H; Qiu L; Di W
    Cytopathology; 2019 Jul; 30(4):419-425. PubMed ID: 31069857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions.
    Virtanen E; Kalliala I; Dyba T; Nieminen P; Auvinen E
    Acta Obstet Gynecol Scand; 2017 Jan; 96(1):61-68. PubMed ID: 27858961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical performance of primary HPV screening cut-off for colposcopy referrals in HPV-vaccinated cohort: Observational study.
    Beecroft M; Gurumurthy M; Cruickshank ME
    BJOG; 2023 Jan; 130(2):210-213. PubMed ID: 36054732
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-risk HPV platforms and test of cure: should specific HPV platforms more suited to screening in a 'test of cure' scenario be recommended?
    Innamaa A; Dudding N; Ellis K; Crossley J; Smith JH; Tidy JA; Palmer JE
    Cytopathology; 2015 Dec; 26(6):381-7. PubMed ID: 25412857
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of self-collected vaginal specimens for the detection of high-risk human papillomavirus infection and the prediction of high-grade cervical intraepithelial lesions in a high-burden, low-resource setting.
    Toliman PJ; Kaldor JM; Badman SG; Phillips S; Tan G; Brotherton JML; Saville M; Vallely AJ; Tabrizi SN
    Clin Microbiol Infect; 2019 Apr; 25(4):496-503. PubMed ID: 29906593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reflex high-risk human papilloma virus DNA test is useful in the triage of women with atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion.
    Wu HH; Allen SL; Kirkpatrick JL; Elsheikh TM
    Diagn Cytopathol; 2006 Oct; 34(10):707-10. PubMed ID: 16955480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of colposcopy after the addition of human papillomavirus testing to the Turkish cervical cancer screening program.
    Gunes AC; Ozgul N; Turkyılmaz M; Kara F; Unlu F; Ayhan A; Gultekin M
    Cancer Med; 2023 Dec; 12(24):21751-21760. PubMed ID: 37994572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
    Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-risk HPV testing vs liquid-based cytology for cervical cancer screening among 25- to 30-year-old women: A historical cohort study.
    Feldstein O; Gali-Zamir H; Schejter E; Feinberg T; Yehuda-Shnaidman E; Bornstein J; Levy T
    Acta Obstet Gynecol Scand; 2023 Feb; 102(2):226-233. PubMed ID: 36478537
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Colposcopic Biopsy Results of Patients Who have Cytomorphological Normal but HPV 16-18 or Other High-Risk HPV Subtypes Positive.
    Aydoğmuş H; Aydoğmuş S
    Asian Pac J Cancer Prev; 2019 Feb; 20(2):417-420. PubMed ID: 30803201
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Co-testing in cervical screening among 40- to 42-year-old women is unreasonable.
    Borgfeldt C; Leksell A; Forslund O
    Acta Obstet Gynecol Scand; 2022 Mar; 101(3):374-378. PubMed ID: 34988970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study.
    Gilbert L; Ratnam S; Jang D; Alaghehbandan R; Schell M; Needle R; Ecobichon-Morris A; Wadhawan A; Costescu D; Elit L; Wang P; Zahariadis G; Chernesky M
    Cancer Biomark; 2022; 34(3):347-358. PubMed ID: 35001877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 58. Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study.
    Reinholdt K; Juul KE; Dehlendorff C; Munk C; Kjaer SK; Thomsen LT
    Acta Obstet Gynecol Scand; 2020 Feb; 99(2):204-212. PubMed ID: 31562779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The necessity of continuing cervical cancer screening of elderly Korean women aged 65 years or older.
    Cho S; Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
    Diagn Cytopathol; 2022 Oct; 50(10):482-490. PubMed ID: 35907183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.